[Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV.

Autor:	Martín-Zaragoza L; Servicio de Farmacia, Hospital Universitario de Getafe, Getafe, Spain. Electronic address: lmartinz@salud.madrid.org., Sánchez-Rubio-Ferrández J; Servicio de Farmacia, Hospital Universitario de Getafe, Getafe, Spain., Onteniente-González A; Servicio de Farmacia, Hospital Universitario de Getafe, Getafe, Spain., Gómez-Bermejo M; Servicio de Farmacia, Hospital Universitario de Getafe, Getafe, Spain., Rodríguez-Álvarez SJ; Servicio de Medicina Interna, Hospital Universitario de Getafe, Getafe, Spain., Monereo-Alonso A; Servicio de Medicina Interna, Hospital Universitario de Getafe, Getafe, Spain., Molina-García T; Servicio de Farmacia, Hospital Universitario de Getafe, Getafe, Spain.
Jazyk:	English; Spanish; Castilian
Zdroj:	Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2024 Jul-Aug; Vol. 48 (4), pp. T171-T175. Date of Electronic Publication: 2024 May 27.
DOI:	10.1016/j.farma.2024.02.016
Abstrakt:	Objetives: The main objective was to compare the persistence between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir-alafenamide (BIC/FTC/TAF) and to analyze reasons for discontinuation. Methods: We conducted a retrospective, non-interventional, descriptive, and longitudinal study. All human immunodeficiency virus (HIV) patients over 18 years treated with DTG/3TC or BIC/FTC/TAF in our center were included. Persistence after first year was compared using the χ 2 test. Kaplan-Meier survival analysis was performed. Results: Three hundred fifty-eight patients were included. 99.5% versus 90.99% of patients were persistent after the first year for DTG/3TC and BIC/FTC/TAF respectively (p=.001). Persistence with DGT/3TC was 1237 days (IC95% 1216-1258) and persistence with BIC/FTC/TAF was 986 days [(IC95% 950-1021); p<.001]. The difference was remained after adjusting for covariates with the cox regression model [HR=8.2 (IC95% 1.03-64.9), p=.047]. The main reasons for discontinuation for BIC/FTC/TAF were toxicity/tolerability. Conclusion: In our study, patients have a high persistence. Patients on DTG/3TC treatment are more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF is tolerability/toxicity. Competing Interests: Declaration of competing interest The authors have declared no conflict of interest. (Copyright © 2024 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu